SL
Siren LLC Portfolio holdings
AUM
$1.93B
This Quarter Return
+22.44%
1 Year Return
+118.08%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$2B
AUM Growth
–
Cap. Flow
+$2B
Cap. Flow
% of AUM
100%
Top 10 Holdings %
Top 10 Hldgs %
41.3%
Holding
110
New
109
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
Kymera Therapeutics
KYMR
|
$141M |
| 2 |
ONC
BeOne Medicines Ltd. American Depositary Shares
ONC
|
$126M |
| 3 |
Scholar Rock
SRRK
|
$90.2M |
| 4 |
BCAX
Bicara Therapeutics Inc. Common Stock
BCAX
|
$78.3M |
| 5 |
argenx
ARGX
|
$77.9M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 93.6% |
| 2 | Technology | 2.88% |
| 3 | Communication Services | 1.83% |
| 4 | Consumer Discretionary | 0.77% |
| 5 | Real Estate | 0.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Cytokinetics
CYTK
$5.98B
| $27.8M | 1.39% |
+525,971
| New | +$27.8M |
|
27
Kura Oncology
KURA
$732M
| $26.2M | 1.31% |
+1,339,942
| New | +$26.2M |
|
28
Arcus Biosciences
RCUS
$1.24B
| $24.6M | 1.23% |
+1,612,077
| New | +$24.6M |
|
29
Denali Therapeutics
DNLI
$2.24B
| $24.3M | 1.21% |
+834,028
| New | +$24.3M |
|
30
Erasca
ERAS
$406M
| $24.2M | 1.21% |
+8,857,179
| New | +$24.2M |
|
31
Cullinan Oncology
CGEM
$456M
| $20.3M | 1.01% |
+1,211,357
| New | +$20.3M |
|
32
Tango Therapeutics
TNGX
$745M
| $20.1M | 1% |
+2,603,897
| New | +$20.1M |
|
33
Solid Biosciences
SLDB
$448M
| $19.2M | 0.96% |
+2,749,041
| New | +$19.2M |
|
34
Prothena Corp
PRTA
$452M
| $18.4M | 0.92% |
+1,099,840
| New | +$18.4M |
|
35
NewAmsterdam Pharma
NAMS
$2.8B
| $15.3M | 0.76% |
+920,564
| New | +$15.3M |
|
36
Biohaven
BHVN
$1.71B
| $14.2M | 0.71% |
+283,540
| New | +$14.2M |
|
37
Korro Bio
KRRO
$244M
| $14M | 0.7% |
+418,833
| New | +$14M |
|
38
Applied Therapeutics
APLT
$73.7M
| $13.9M | 0.69% |
+1,633,768
| New | +$13.9M |
|
39
Gossamer Bio
GOSS
$587M
| $13.1M | 0.65% |
+13,281,610
| New | +$13.1M |
|
40
Instil Bio
TIL
$196M
| $13M | 0.65% |
+192,433
| New | +$13M |
|
41
Edgewise Therapeutics
EWTX
$1.54B
| $10.8M | 0.54% |
+404,113
| New | +$10.8M |
|
42
Iovance Biotherapeutics
IOVA
$800M
| $10.4M | 0.52% |
+1,106,040
| New | +$10.4M |
|
43
Oric Pharmaceuticals
ORIC
$1.03B
| $10.3M | 0.52% |
+1,007,575
| New | +$10.3M |
|
44
Ionis Pharmaceuticals
IONS
$9.64B
| $10M | 0.5% |
+250,000
| New | +$10M |
|
45
Taysha Gene Therapies
TSHA
$791M
| $9.81M | 0.49% |
+4,879,875
| New | +$9.81M |
|
46
Microsoft
MSFT
$3.76T
| $9.46M | 0.47% |
+22,000
| New | +$9.46M |
|
47
Cartesian Therapeutics
RNAC
$267M
| $9.22M | 0.46% |
+572,236
| New | +$9.22M |
|
|
SLRN
48
DELISTED
ACELYRIN
SLRN
| $8.53M | 0.43% |
+1,729,665
| New | +$8.53M |
|
49
Phathom Pharmaceuticals
PHAT
$843M
| $8.33M | 0.42% |
+460,753
| New | +$8.33M |
|
50
Seer Inc
SEER
$114M
| $7.88M | 0.39% |
+4,000,000
| New | +$7.88M |
|